Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FBP1 | P09467 | 14/20 | 0.67 |
| ▸ | VCP | P55072 | 3/20 | 0.53 |
| ▸ | EGFR | P00533 | 2/20 | 0.48 |
| ▸ | ABL1 | P00519 | 1/20 | 0.48 |
| ▸ | ABL2 | P42684 | 1/20 | 0.48 |
| ▸ | MITF | O75030 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.45 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.45 |
| ▸ | MAPT | P10636 | 1/20 | 0.45 |
| ▸ | HTT | P42858 | 1/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2285892 | 1.00 | FBP1 (0.67) | FBP1VCPEGFRABL1ABL2 | |
| SCHEMBL3241242 | 0.87 | FBP1 (0.57) | FBP1VCPEGFRABL1ABL2 | |
| SCHEMBL3241249 | 0.87 | FBP1 (0.57) | FBP1VCPEGFRABL1ABL2 | |
| SCHEMBL23684551 | 0.82 | FBP1 (0.60) | FBP1VCPEGFRALDH1A1MAPT | |
| SCHEMBL1722327 | 0.81 | FBP1 (0.57) | FBP1VCPEGFRABL1ABL2 | |
| SCHEMBL29007465 | 0.81 | FBP1 (0.57) | FBP1VCPEGFRABL1ABL2 | |
| SCHEMBL1722329 | 0.81 | FBP1 (0.57) | FBP1VCPEGFRABL1ABL2 | |
| SCHEMBL527534 | 0.80 | FBP1 (1.00) | FBP1VCP | |
| SCHEMBL527535 | 0.80 | FBP1 (1.00) | FBP1VCP | |
| SCHEMBL102630 | 0.78 | FBP1 (1.00) | FBP1VCPEGFRABL1ABL2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 35 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230138795-A1 | DOPAMINE-B-HYDROXYLASE INHIBITORS | BIAL PORTELA & CA SA (PT) | 2023-05-04 | — | — | US | disclosed |
| US-11434242-B2 | Dopamine-b-hydroxylase inhibitors | BIAL—PORTELA & CA, S.A. (PT) | 2022-09-06 | — | — | US | disclosed |
| CN-109715633-B | Dopamine-beta-hydroxylase inhibitors | 巴尔-波特拉及康邦亚股份有限公司 | 2022-03-04 | — | — | CN | disclosed |
| US-20220017523-A1 | BLOOD-BRAIN BARRIER-PENETRANT DOPAMINE-ß-HYDROXYLASE INHIBITORS | BIAL - PORTELA & CA, S.A. (PT) | 2022-01-20 | — | — | US | disclosed |
| US-11034695-B2 | Dopamine-β-hydroxylase inhibitors | BIAL—Portela & Cᵃ, S.A. (PT) | 2021-06-15 | — | — | US | disclosed |
| US-20210171528-A1 | DOPAMINE-B-HYDROXYLASE INHIBITORS | BIAL - PORTELA & CA, S.A. (PT) | 2021-06-10 | — | — | US | disclosed |
| US-10975083-B2 | Blood-brain barrier-penetrant dopamine-β-hydroxylase inhibitors | BIAL—PORTELA & CA, S.A. (PT) | 2021-04-13 | — | — | US | disclosed |
| EP-3720856-A1 | DOPAMINE-& X392;-HYDROXYLASE INHIBITORS | BIAL - PORTELA & Cª, S.A. (PT) | 2020-10-14 | — | — | EP | disclosed |
| CN-111479812-A | dopamine-B-hydroxylase inhibitors | 巴尔-波特拉及康邦亚股份有限公司 | 2020-07-31 | — | — | CN | disclosed |
| US-20200181148-A1 | DOPAMINE-B-HYDROXYLASE INHIBITORS | BIAL-PORTELA & CA, S.A. (PT) | 2020-06-11 | — | — | US | disclosed |
| EP-2091928-A2 | 3-(2-ACYLAMINO-1-HYDROXYETHYL)- MORPHOLINE DERIVATIVES AND THEIR USE AS BACE INHIBITORS | ELI LILLY AND COMPANY (US) | 2009-08-26 | — | — | EP | disclosed |
| US-20070225267-A1 | 3-(2-Acylamino-1-Hydroxyethyl)-Morpholine Derivatives and Their Use as Bace Inhibitors | ELI LILLY AND COMPANY | 2007-09-27 | — | — | US | disclosed |
| US-20070225372-A1 | Amides as Bace Inhibitors | ELI LILLY AND COMPANY | 2007-09-27 | — | — | US | disclosed |
| US-20070213331-A1 | PYRROLIDINE DERIVATIVES USEFUL AS BASE INHIBITORS | ELI LILLY AND COMPANY | 2007-09-13 | — | — | US | disclosed |
| EP-1740575-A2 | PYRROLIDINE DERIVATIVES USEFUL AS BACE INHIBITORS | ELI LILLY AND COMPANY (US) | 2007-01-10 | — | — | EP | disclosed |
| EP-1740573-A1 | AMIDES AS BACE INHIBITORS | ELI LILLY AND COMPANY (US) | 2007-01-10 | — | — | EP | disclosed |
| WO-2006034093-A2 | 3- (2-ACYLAMINO-1-HYDROXYETHYL)- MORPHOLINE DERIVATIVES AND THEIR USE AS BACE INHIBITORS | ELLI LILLY AND COMPANY (US) | 2006-03-30 | — | — | WO | disclosed |
| US-20060040936-A1 | Substituted N-arylsulfonylheterocyclic amines as gamma-secretase inhibitors | SCHERING CORPORATION | 2006-02-23 | — | — | US | disclosed |
| WO-2005108391-A1 | AMIDES AS BACE INHIBITORS | ELI LILLY AND COMPANY (US) | 2005-11-17 | — | — | WO | disclosed |
| WO-2005108358-A2 | PYRROLIDINE DERIVATIVES USEFUL AS BACE INHIBITORS | ELI LILLY AND COMPANY (US) | 2005-11-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220017523-A1 | BLOOD-BRAIN BARRIER-PENETRANT DOPAMINE-ß-HYDROXYLASE INHIBITORS | DBH, SLC6A3, SLC6A2 | FBP1 2246/4885VCP 3927/4885EGFR 2116/4885 |
| US-20070225372-A1 | Amides as Bace Inhibitors | BACE2, BACE1, APP | FBP1 752/4885VCP 2501/4885EGFR 110/4885 |
| US-20070225267-A1 | 3-(2-Acylamino-1-Hydroxyethyl)-Morpholine Derivatives and Their Use as Bace Inhibitors | BACE1, BACE2, APP | FBP1 2487/4885VCP 1344/4885EGFR 1332/4885 |
| US-11434242-B2 | Dopamine-b-hydroxylase inhibitors | DBH, MAOB, COMT | FBP1 2193/4885VCP 3760/4885EGFR 2453/4885 |
| US-20070213331-A1 | PYRROLIDINE DERIVATIVES USEFUL AS BASE INHIBITORS | BACE1, BACE2, PSEN1 | FBP1 388/4885VCP 1784/4885EGFR 1101/4885 |
| US-20230138795-A1 | DOPAMINE-B-HYDROXYLASE INHIBITORS | DBH, MAOB, COMT | FBP1 2316/4885VCP 3606/4885EGFR 2532/4885 |
| US-10975083-B2 | Blood-brain barrier-penetrant dopamine-β-hydroxylase inhibitors | DBH, SLC6A3, SLC6A2 | FBP1 2345/4885VCP 4081/4885EGFR 2051/4885 |
| US-20200181148-A1 | DOPAMINE-B-HYDROXYLASE INHIBITORS | DBH, MAOB, SLC6A3 | FBP1 2077/4885VCP 3848/4885EGFR 2610/4885 |
| US-20060040936-A1 | Substituted N-arylsulfonylheterocyclic amines as gamma-secretase inhibitors | BACE1, BACE2, APP | FBP1 4527/4885VCP 3343/4885EGFR 204/4885 |
| US-11034695-B2 | Dopamine-β-hydroxylase inhibitors | DBH, SLC6A3, COMT | FBP1 2447/4885VCP 3734/4885EGFR 2481/4885 |
| US-20210171528-A1 | DOPAMINE-B-HYDROXYLASE INHIBITORS | DBH, MAOB, COMT | FBP1 2193/4885VCP 3760/4885EGFR 2453/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.